Literature DB >> 17195140

Usual interstitial pneumonia.

Joseph P Lynch1, Rajan Saggar, S Sam Weigt, David A Zisman, Eric S White.   

Abstract

Usual interstitial pneumonia (UIP) is a distinct histological lesion observed in idiopathic pulmonary fibrosis (IPF) but can be found in other etiologies. The diagnosis of UIP can be established by surgical lung biopsy or by high-resolution thin-section computed tomographic (CT) scans (provided the radiographic features are classical). Historically, patients labeled as "IPF" encompassed a group of disorders, including UIP as well as other idiopathic interstitial pneumonias that differ from UIP in prognosis and responsiveness to therapy. Current recommendations from international consensus statements restrict the term IPF to patients with idiopathic UIP. The inciting cause(s) and pathogenesis of UIP have not been elucidated, but alveolar epithelial cell injury and dysregulation or altered phenotypic expression of fibroblasts are key elements. Inflammatory cells may play minor roles in initiating or propagating the fibrotic process. The prognosis of UIP is poor. Mean survival following diagnosis approximates 3 years. Current therapies are of unproven value. Corticosteroids or immunosuppressive agents have been most often used, but data affirming benefit are lacking. Lung transplantation is a viable option for patients failing medical therapy. This review discusses diagnostic criteria for UIP (both histopathological and radiographic), natural history and clinical course, and therapeutic approaches (both current and future).

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17195140     DOI: 10.1055/s-2006-957335

Source DB:  PubMed          Journal:  Semin Respir Crit Care Med        ISSN: 1069-3424            Impact factor:   3.119


  19 in total

1.  An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.

Authors:  Ganesh Raghu; Harold R Collard; Jim J Egan; Fernando J Martinez; Juergen Behr; Kevin K Brown; Thomas V Colby; Jean-François Cordier; Kevin R Flaherty; Joseph A Lasky; David A Lynch; Jay H Ryu; Jeffrey J Swigris; Athol U Wells; Julio Ancochea; Demosthenes Bouros; Carlos Carvalho; Ulrich Costabel; Masahito Ebina; David M Hansell; Takeshi Johkoh; Dong Soon Kim; Talmadge E King; Yasuhiro Kondoh; Jeffrey Myers; Nestor L Müller; Andrew G Nicholson; Luca Richeldi; Moisés Selman; Rosalind F Dudden; Barbara S Griss; Shandra L Protzko; Holger J Schünemann
Journal:  Am J Respir Crit Care Med       Date:  2011-03-15       Impact factor: 21.405

Review 2.  Treatment of Systemic Sclerosis-related Interstitial Lung Disease: A Review of Existing and Emerging Therapies.

Authors:  Elizabeth R Volkmann; Donald P Tashkin
Journal:  Ann Am Thorac Soc       Date:  2016-11

3.  Automated classification of usual interstitial pneumonia using regional volumetric texture analysis in high-resolution computed tomography.

Authors:  Adrien Depeursinge; Anne S Chin; Ann N Leung; Donato Terrone; Michael Bristow; Glenn Rosen; Daniel L Rubin
Journal:  Invest Radiol       Date:  2015-04       Impact factor: 6.016

4.  Dynamic expression of transformating growth factor-β1 and caveolin-1 in the lung of Bleomycin-induced interstitial lung disease.

Authors:  Yida Xing; Li Wang; Hongjiang Wang; Xiaodan Kong; Libin Zhan
Journal:  J Thorac Dis       Date:  2017-08       Impact factor: 2.895

5.  Rheumatoid arthritis-interstitial lung disease-associated mortality.

Authors:  Amy L Olson; Jeffrey J Swigris; David B Sprunger; Aryeh Fischer; Evans R Fernandez-Perez; Josh Solomon; James Murphy; Marc Cohen; Ganesh Raghu; Kevin K Brown
Journal:  Am J Respir Crit Care Med       Date:  2010-09-17       Impact factor: 21.405

6.  VCAM-1 is a TGF-β1 inducible gene upregulated in idiopathic pulmonary fibrosis.

Authors:  Marianna Agassandian; John R Tedrow; John Sembrat; Daniel J Kass; Yingze Zhang; Elena A Goncharova; Naftali Kaminski; Rama K Mallampalli; Louis J Vuga
Journal:  Cell Signal       Date:  2015-09-18       Impact factor: 4.315

Review 7.  Current concepts in disease-modifying therapy for systemic sclerosis-associated interstitial lung disease: lessons from clinical trials.

Authors:  Karen Au; Dinesh Khanna; Philip J Clements; Daniel E Furst; Donald P Tashkin
Journal:  Curr Rheumatol Rep       Date:  2009-04       Impact factor: 4.592

Review 8.  Interstitial lung disease in connective tissue diseases: evolving concepts of pathogenesis and management.

Authors:  Flavia V Castelino; John Varga
Journal:  Arthritis Res Ther       Date:  2010-08-23       Impact factor: 5.156

9.  Serum albumin concentration and waiting list mortality in idiopathic interstitial pneumonia.

Authors:  David A Zisman; Steven M Kawut; David J Lederer; John A Belperio; Joseph P Lynch; Marvin I Schwarz; John A Tayek; David B Reuben; Arun S Karlamangla
Journal:  Chest       Date:  2008-11-18       Impact factor: 9.410

10.  WNT5A is a regulator of fibroblast proliferation and resistance to apoptosis.

Authors:  Louis J Vuga; Ahmi Ben-Yehudah; Elizabetha Kovkarova-Naumovski; Timothy Oriss; Kevin F Gibson; Carol Feghali-Bostwick; Naftali Kaminski
Journal:  Am J Respir Cell Mol Biol       Date:  2009-02-27       Impact factor: 6.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.